Next Article in Journal
A Green Slab Waveguide for Plasmonic Sensors Based on Bacterial Cellulose
Previous Article in Journal
Amaryllidaceae Alkaloids from Zephyrantes Carinata and Their Evaluation as Cholinesterases (AChE and BChE) Inhibitors
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Extended Abstract

Development of Novel, Potent Phosphatidyl–Choline-Specific Phospholipase C Inhibitors †

1
School of Chemical Sciences, University of Auckland, Auckland 1142, New Zealand
2
Auckland Cancer Society Research Centre, University of Auckland, Grafton, Auckland 1023, New Zealand
*
Author to whom correspondence should be addressed.
Presented at the 2nd Molecules Medicinal Chemistry Symposium (MMCS): Facing Novel Challenges in Drug Discovery, Barcelona, Spain, 15–17 May 2019.
Proceedings 2019, 22(1), 67; https://doi.org/10.3390/proceedings2019022067
Published: 12 August 2019

Abstract

:
The phosphatidyl–choline-specific phospholipase C (PC-PLC) enzyme has been shown to be an important enzyme involved in various cell-signaling processes. Furthermore, PC-PLC has been shown to be upregulated in various cancer cell lines, thereby presenting itself as a potential anti-cancer therapeutic target. Current PC-PLC inhibitors, including the literature standard inhibitor D609 possess characteristics making them unsuitable for clinical use. We have discovered a new class of potent PC-PLC inhibitors with much improved activity and drug-like properties than D609. The synthesis and SAR study of this class of active compounds is presented.

The association of the abnormal metabolism of choline-containing phospholipids with various cancers has resulted in the identification of enzymes involved in the phosphocholine cycle as potential therapeutic targets. Phosphatidyl–choline-specific phospholipase C (PC-PLC) plays a pivotal role in this cycle and has been implicated in many signalling processes, demonstrating overexpression in various cancerous tumors, thus providing a viable target for inhibition of cancer cell growth. It has been reported that PC-PLC activation accounts for 20–50% of the intracellular phosphocholine production in ovarian and breast cancer cells of different subtypes.
By virtue of virtual high throughput screening, a number of lead compounds were identified as inhibitors of the PC-PLC enzyme, all of which were identified to bind to key zinc atoms at the active site. To study the PC-PLC inhibitory activity of these compounds and to verify their SAR, an extensive range of novel analogues have been synthesized, varying a number of different structural features.
Analysis of the biological activity of the synthesized analogues showed significantly improved inhibitory activity over the only well-documented PC-PLC inhibitor, D609. These results, as well as the antiproliferative activities of the synthesised compounds, will be reported, providing a comprehensive SAR of these potent compounds and their potential therapeutic applications.

Share and Cite

MDPI and ACS Style

Pilkington, L.I.; Leung, E.; Barker, D. Development of Novel, Potent Phosphatidyl–Choline-Specific Phospholipase C Inhibitors. Proceedings 2019, 22, 67. https://doi.org/10.3390/proceedings2019022067

AMA Style

Pilkington LI, Leung E, Barker D. Development of Novel, Potent Phosphatidyl–Choline-Specific Phospholipase C Inhibitors. Proceedings. 2019; 22(1):67. https://doi.org/10.3390/proceedings2019022067

Chicago/Turabian Style

Pilkington, Lisa I., Euphemia Leung, and David Barker. 2019. "Development of Novel, Potent Phosphatidyl–Choline-Specific Phospholipase C Inhibitors" Proceedings 22, no. 1: 67. https://doi.org/10.3390/proceedings2019022067

APA Style

Pilkington, L. I., Leung, E., & Barker, D. (2019). Development of Novel, Potent Phosphatidyl–Choline-Specific Phospholipase C Inhibitors. Proceedings, 22(1), 67. https://doi.org/10.3390/proceedings2019022067

Article Metrics

Back to TopTop